Exact Mass: 514.2388968

Exact Mass Matches: 514.2388968

Found 152 metabolites which its exact mass value is equals to given mass value 514.2388968, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Telmisartan

2-(4-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid

C33H30N4O2 (514.236864)


Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 2805 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.

   

Protoasukamycin

Protoasukamycin

C31H34N2O5 (514.2467594)


A polyketide that is (all-E)-7-(3-amino-4-hydroxyphenyl)hepta-2,4,6-trienoic acid in which the amino group has been acylated by an (all-E)-7-cyclohexylhepta-2,4,6-trienoyl group and in which the carboxy group has undergone formal condensation with the amino group of 2-amino-3-hydroxycyclopent-2-en-1-one to give the corresponding carboxamide. Protoasukamycin is an intermediate in the biosynthesis of asukamycin.

   

PA(2:0/20:4(6E,8Z,11Z,14Z)+=O(5))

[(2R)-3-(acetyloxy)-2-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(2:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0)

[(2R)-2-(acetyloxy)-3-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(5Z,8Z,11Z,13E)+=O(15))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(2:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

[(2R)-3-(acetyloxy)-2-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0)

[(2R)-2-(acetyloxy)-3-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}propoxy]phosphonic acid

C25H39O9P (514.2331574)


PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   

4-butyl 1-(4-beta-D-glucopyranosyloxy-benzyl)ester (2R)-2-hydroxy-2-(2-methylpropyl)-butanedioic acid|armatuside|bletillin A

4-butyl 1-(4-beta-D-glucopyranosyloxy-benzyl)ester (2R)-2-hydroxy-2-(2-methylpropyl)-butanedioic acid|armatuside|bletillin A

C25H38O11 (514.2413998)


   

15-isobutyrylhenrycinol A|henrycinol B

15-isobutyrylhenrycinol A|henrycinol B

C31H34N2O5 (514.2467594)


   

6R,7-dihydro-10-O-foliamenthoylaucubin

6R,7-dihydro-10-O-foliamenthoylaucubin

C25H38O11 (514.2413998)


   
   

akuammidine 17-O-beta-d-glucopyranoside|methyl (19E)-17-(b-d-glucopyranosyloxy)-10-hydroxysarpagan-16-carboxylate

akuammidine 17-O-beta-d-glucopyranoside|methyl (19E)-17-(b-d-glucopyranosyloxy)-10-hydroxysarpagan-16-carboxylate

C27H34N2O8 (514.2315044000001)


   
   
   
   
   

Telmisartan

Telmisartan aka 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid

C33H30N4O2 (514.236864)


C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 2251 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 63 CONFIDENCE standard compound; INTERNAL_ID 8191 This spectrum was obtained at The Multidisciplinary Research Laboratory at Antenor Orrego Private University, Trujillo, La Libertad, Peru.The sample was obtained from a pharmacy.; The sample was dissolved in 1:1 acetonitrile:water and passed through a ACQUITY UPLC BEH C18 1.7um column at 0.6 mL/min in ramp of MPA: 0.1\\\% Formic Acid in water; MPB: 0.1\\\% Formic Acid in Acetonitrile; Contact us: http://www.upao.edu.pe/labinm/ Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.

   

Ala Val Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Ala Tyr Val Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Ala Tyr Tyr Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanoic acid

C26H34N4O7 (514.2427374)


   

Cys His Lys Gln

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]hexanamido]-4-carbamoylbutanoic acid

C20H34N8O6S (514.2321904)


   

Cys His Gln Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-4-carbamoylbutanamido]hexanoic acid

C20H34N8O6S (514.2321904)


   

Cys Lys His Gln

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-3-(1H-imidazol-4-yl)propanamido]-4-carbamoylbutanoic acid

C20H34N8O6S (514.2321904)


   

Cys Lys Gln His

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-4-carbamoylbutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H34N8O6S (514.2321904)


   

Cys Gln His Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carbamoylbutanamido]-3-(1H-imidazol-4-yl)propanamido]hexanoic acid

C20H34N8O6S (514.2321904)


   

Cys Gln Lys His

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carbamoylbutanamido]hexanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H34N8O6S (514.2321904)


   

Phe Phe Thr Thr

(2S,3R)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-3-hydroxybutanoic acid

C26H34N4O7 (514.2427374)


   

Phe Ser Val Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxypropanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Phe Ser Tyr Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanoic acid

C26H34N4O7 (514.2427374)


   

Phe Thr Phe Thr

(2S,3R)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C26H34N4O7 (514.2427374)


   

Phe Thr Thr Phe

(2S)-2-[(2S,3R)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C26H34N4O7 (514.2427374)


   

Phe Val Ser Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylbutanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Phe Val Tyr Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanoic acid

C26H34N4O7 (514.2427374)


   

Phe Tyr Ser Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-methylbutanoic acid

C26H34N4O7 (514.2427374)


   

Phe Tyr Val Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-hydroxypropanoic acid

C26H34N4O7 (514.2427374)


   

Gly Ile Tyr Tyr

(2S)-2-[(2S)-2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Gly Leu Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Gly Tyr Ile Tyr

(2S)-2-[(2S,3S)-2-[(2S)-2-(2-aminoacetamido)-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Gly Tyr Leu Tyr

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(4-hydroxyphenyl)propanamido]-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Gly Tyr Tyr Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylpentanoic acid

C26H34N4O7 (514.2427374)


   

Gly Tyr Tyr Leu

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-4-methylpentanoic acid

C26H34N4O7 (514.2427374)


   

His Cys Lys Gln

(2S)-2-[(2S)-6-amino-2-[(2R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]hexanamido]-4-carbamoylbutanoic acid

C20H34N8O6S (514.2321904)


   

His Cys Gln Lys

(2S)-6-amino-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]-4-carbamoylbutanamido]hexanoic acid

C20H34N8O6S (514.2321904)


   

His Lys Cys Gln

(2S)-2-[(2R)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]hexanamido]-3-sulfanylpropanamido]-4-carbamoylbutanoic acid

C20H34N8O6S (514.2321904)


   

His Lys Gln Cys

(2R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]hexanamido]-4-carbamoylbutanamido]-3-sulfanylpropanoic acid

C20H34N8O6S (514.2321904)


   

His Gln Cys Lys

(2S)-6-amino-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-4-carbamoylbutanamido]-3-sulfanylpropanamido]hexanoic acid

C20H34N8O6S (514.2321904)


   

His Gln Lys Cys

(2R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-4-carbamoylbutanamido]hexanamido]-3-sulfanylpropanoic acid

C20H34N8O6S (514.2321904)


   

Ile Gly Tyr Tyr

(2S)-2-[(2S)-2-{2-[(2S,3S)-2-amino-3-methylpentanamido]acetamido}-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Ile Tyr Gly Tyr

(2S)-2-{2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-(4-hydroxyphenyl)propanamido]acetamido}-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Ile Tyr Tyr Gly

2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]acetic acid

C26H34N4O7 (514.2427374)


   

Lys Cys His Gln

(2S)-4-carbamoyl-2-[(2S)-2-[(2R)-2-[(2S)-2,6-diaminohexanamido]-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]butanoic acid

C20H34N8O6S (514.2321904)


   

Lys Cys Gln His

(2S)-2-[(2S)-4-carbamoyl-2-[(2R)-2-[(2S)-2,6-diaminohexanamido]-3-sulfanylpropanamido]butanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H34N8O6S (514.2321904)


   

Lys His Cys Gln

(2S)-4-carbamoyl-2-[(2R)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]butanoic acid

C20H34N8O6S (514.2321904)


   

Lys His Gln Cys

(2R)-2-[(2S)-4-carbamoyl-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-imidazol-4-yl)propanamido]butanamido]-3-sulfanylpropanoic acid

C20H34N8O6S (514.2321904)


   

Lys Gln Cys His

(2S)-2-[(2R)-2-[(2S)-4-carbamoyl-2-[(2S)-2,6-diaminohexanamido]butanamido]-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H34N8O6S (514.2321904)


   

Lys Gln His Cys

(2R)-2-[(2S)-2-[(2S)-4-carbamoyl-2-[(2S)-2,6-diaminohexanamido]butanamido]-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanoic acid

C20H34N8O6S (514.2321904)


   

Leu Gly Tyr Tyr

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-4-methylpentanamido]acetamido}-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Leu Tyr Gly Tyr

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-(4-hydroxyphenyl)propanamido]acetamido}-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Leu Tyr Tyr Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]acetic acid

C26H34N4O7 (514.2427374)


   

Gln Cys His Lys

(2S)-6-amino-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]hexanoic acid

C20H34N8O6S (514.2321904)


   

Gln Cys Lys His

(2S)-2-[(2S)-6-amino-2-[(2R)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-sulfanylpropanamido]hexanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H34N8O6S (514.2321904)


   

Gln His Cys Lys

(2S)-6-amino-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]hexanoic acid

C20H34N8O6S (514.2321904)


   

Gln His Lys Cys

(2R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(1H-imidazol-4-yl)propanamido]hexanamido]-3-sulfanylpropanoic acid

C20H34N8O6S (514.2321904)


   

Gln Lys Cys His

(2S)-2-[(2R)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-carbamoylbutanamido]hexanamido]-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H34N8O6S (514.2321904)


   

Gln Lys His Cys

(2R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-carbamoylbutanamido]hexanamido]-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanoic acid

C20H34N8O6S (514.2321904)


   

Ser Phe Val Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-phenylpropanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Ser Phe Tyr Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanoic acid

C26H34N4O7 (514.2427374)


   

Ser Val Phe Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylbutanamido]-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Ser Val Tyr Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanoic acid

C26H34N4O7 (514.2427374)


   

Ser Tyr Phe Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]-3-methylbutanoic acid

C26H34N4O7 (514.2427374)


   

Ser Tyr Val Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-phenylpropanoic acid

C26H34N4O7 (514.2427374)


   

Thr Phe Phe Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C26H34N4O7 (514.2427374)


   

Thr Phe Thr Phe

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C26H34N4O7 (514.2427374)


   

Thr Thr Phe Phe

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C26H34N4O7 (514.2427374)


   

Val Ala Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Val Phe Ser Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-phenylpropanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Val Phe Tyr Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanoic acid

C26H34N4O7 (514.2427374)


   

Val Ser Phe Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxypropanamido]-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Val Ser Tyr Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanoic acid

C26H34N4O7 (514.2427374)


   

Val Tyr Ala Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Val Tyr Phe Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]-3-hydroxypropanoic acid

C26H34N4O7 (514.2427374)


   

Val Tyr Ser Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-phenylpropanoic acid

C26H34N4O7 (514.2427374)


   

Val Tyr Tyr Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]propanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Ala Val Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Ala Tyr Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Phe Ser Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]-3-hydroxypropanamido]-3-methylbutanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Phe Val Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]-3-methylbutanamido]-3-hydroxypropanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Gly Ile Tyr

(2S)-2-[(2S,3S)-2-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}-3-methylpentanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Gly Leu Tyr

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Gly Tyr Ile

(2S,3S)-2-[(2S)-2-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}-3-(4-hydroxyphenyl)propanamido]-3-methylpentanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Gly Tyr Leu

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}-3-(4-hydroxyphenyl)propanamido]-4-methylpentanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Ile Gly Tyr

(2S)-2-{2-[(2S,3S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]acetamido}-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Ile Tyr Gly

2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]-3-(4-hydroxyphenyl)propanamido]acetic acid

C26H34N4O7 (514.2427374)


   

Tyr Leu Gly Tyr

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-4-methylpentanamido]acetamido}-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Leu Tyr Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-4-methylpentanamido]-3-(4-hydroxyphenyl)propanamido]acetic acid

C26H34N4O7 (514.2427374)


   

Tyr Ser Phe Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-phenylpropanamido]-3-methylbutanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Ser Val Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-methylbutanamido]-3-phenylpropanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Val Ala Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanamido]-3-(4-hydroxyphenyl)propanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Val Phe Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-phenylpropanamido]-3-hydroxypropanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Val Ser Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-hydroxypropanamido]-3-phenylpropanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Val Tyr Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]propanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Tyr Ala Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-3-methylbutanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Tyr Gly Ile

(2S,3S)-2-{2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]acetamido}-3-methylpentanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Tyr Gly Leu

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]acetamido}-4-methylpentanoic acid

C26H34N4O7 (514.2427374)


   

Tyr Tyr Ile Gly

2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]acetic acid

C26H34N4O7 (514.2427374)


   

Tyr Tyr Leu Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-4-methylpentanamido]acetic acid

C26H34N4O7 (514.2427374)


   

Tyr Tyr Val Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanoic acid

C26H34N4O7 (514.2427374)


   

DPNGL

Asp Pro Asn Gly Leu

C21H34N6O9 (514.2387154)


   

NGPVE

Asn Gly Pro Val Glu

C21H34N6O9 (514.2387154)


   

2-(chloromethyl)oxirane,4-[2-(4-hydroxyphenyl)propan-2-yl]phenol,2-methyloxirane,oxirane,propane-1,2,3-triol

2-(chloromethyl)oxirane,4-[2-(4-hydroxyphenyl)propan-2-yl]phenol,2-methyloxirane,oxirane,propane-1,2,3-triol

C26H39ClO8 (514.2333324)


   

4,4-(1,2-Ethenediyl)bis[N,N-diphenylbenzenamine]

4,4-(1,2-Ethenediyl)bis[N,N-diphenylbenzenamine]

C38H30N2 (514.240886)


   

hexanedioic acid,hexane-1,6-diol,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene

hexanedioic acid,hexane-1,6-diol,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene

C27H34N2O8 (514.2315044000001)


   

N,N-diphenyl-4-[2-[4-(N-phenylanilino)phenyl]ethenyl]aniline

N,N-diphenyl-4-[2-[4-(N-phenylanilino)phenyl]ethenyl]aniline

C38H30N2 (514.240886)


   

4-[(1,7-Dimethyl-2-propyl[2,5-bi-1H-benzimidazol]-1-yl)methyl][1,1-biphenyl]-2-carboxylic Acid

4-[(1,7-Dimethyl-2-propyl[2,5-bi-1H-benzimidazol]-1-yl)methyl][1,1-biphenyl]-2-carboxylic Acid

C33H30N4O2 (514.236864)


   

hexanedioic acid,hexane-1,6-diol,1-isocyanato-2-[(2-isocyanatophenyl)methyl]benzene

hexanedioic acid,hexane-1,6-diol,1-isocyanato-2-[(2-isocyanatophenyl)methyl]benzene

C27H34N2O8 (514.2315044000001)


   
   

PA(2:0/20:4(6E,8Z,11Z,14Z)+=O(5))

PA(2:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C25H39O9P (514.2331574)


   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0)

C25H39O9P (514.2331574)


   

PA(2:0/20:4(5Z,8Z,11Z,13E)+=O(15))

PA(2:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C25H39O9P (514.2331574)


   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0)

C25H39O9P (514.2331574)


   

PA(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

PA(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C25H39O9P (514.2331574)


   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0)

C25H39O9P (514.2331574)


   

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C25H39O9P (514.2331574)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0)

C25H39O9P (514.2331574)


   

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C25H39O9P (514.2331574)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0)

C25H39O9P (514.2331574)


   

PA(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

PA(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C25H39O9P (514.2331574)


   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0)

C25H39O9P (514.2331574)


   

1-[3-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-4-methoxyphenyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid

1-[3-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-4-methoxyphenyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid

C30H31FN4O3 (514.2380068)


   

1,2-Diheptanoyl-1,2-dithio-sn-glycero-3-phosphocholine

1,2-Diheptanoyl-1,2-dithio-sn-glycero-3-phosphocholine

C22H45NO6PS2+ (514.2425780000001)


   

(4-fluorophenyl)-[(1R)-1-(hydroxymethyl)-7-methoxy-1-(3-pyridinylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone

(4-fluorophenyl)-[(1R)-1-(hydroxymethyl)-7-methoxy-1-(3-pyridinylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone

C30H31FN4O3 (514.2380068)


   

(4-fluorophenyl)-[(1S)-1-(hydroxymethyl)-7-methoxy-1-(3-pyridinylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone

(4-fluorophenyl)-[(1S)-1-(hydroxymethyl)-7-methoxy-1-(3-pyridinylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone

C30H31FN4O3 (514.2380068)


   
   
   
   
   
   
   
   
   

(3s,4as,6s,6ar,7r,10ar,10br)-6a-[(acetyloxy)methyl]-7-(chloromethyl)-7-hydroxy-4a,10b-dimethyl-5'-oxo-octahydrospiro[naphtho[2,1-b]pyran-3,3'-oxolan]-6-yl 2-methylpropanoate

(3s,4as,6s,6ar,7r,10ar,10br)-6a-[(acetyloxy)methyl]-7-(chloromethyl)-7-hydroxy-4a,10b-dimethyl-5'-oxo-octahydrospiro[naphtho[2,1-b]pyran-3,3'-oxolan]-6-yl 2-methylpropanoate

C26H39ClO8 (514.2333324)


   

(2s)-2-{[(2e,4e,6e,8e,10e,12e,14e)-15-{[(1s,2s)-1-carboxy-2-methylbutyl]-c-hydroxycarbonimidoyl}-1-hydroxypentadeca-2,4,6,8,10,12,14-heptaen-1-ylidene]amino}pentanedioic acid

(2s)-2-{[(2e,4e,6e,8e,10e,12e,14e)-15-{[(1s,2s)-1-carboxy-2-methylbutyl]-c-hydroxycarbonimidoyl}-1-hydroxypentadeca-2,4,6,8,10,12,14-heptaen-1-ylidene]amino}pentanedioic acid

C27H34N2O8 (514.2315044000001)